Skip to main content

Advertisement

SpringerLink
Log in

Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study)

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown.

Methods

We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8 ≤ 14) on worse QOL.

Results

The median age of patients was 70 years. There were 369 (surgery: 196, radiotherapy: 156, androgen deprivation therapy alone: 17) patients in the M0 and 40 patients in the mCSPC groups. There was a significant difference between the M0 and mCSPC groups in the G8 score (14.5 vs. 12.5), functioning QOL (94 vs. 87), global QOL (75 vs. 58), and 100–symptom QOL (94 vs. 85) scores. G8 scores were significantly associated with functioning, global, and 100–symptom QOL scores in both M0 and mCSPC groups. The multivariable logistic regression analyses showed that frailty (G8 ≤ 14) was significantly associated with worse global QOL, functioning QOL, and 100–symptom QOL scores.

Conclusion

The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Culp MB, Soerjomataram I, Efstathiou JA et al (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38–52. https://doi.org/10.1016/j.eururo.2019.08.005

    Article  PubMed  Google Scholar 

  2. Kimura T, Egawa S (2018) Epidemiology of prostate cancer in Asian countries. Int J Urol 25(6):524–531. https://doi.org/10.1111/iju.13593

    Article  PubMed  Google Scholar 

  3. Ito K, Oki R, Sekine Y et al (2019) Screening for prostate cancer: history, evidence, controversies and future perspectives toward individualized screening. Int J Urol 26(10):956–970. https://doi.org/10.1111/iju.14039

    Article  PubMed  Google Scholar 

  4. Isharwal S, Johanning JM, Dwyer JG et al (2017) Preoperative frailty predicts postoperative complications and mortality in urology patients. World J Urol 35(1):21–26. https://doi.org/10.1007/s00345-016-1845-z

    Article  PubMed  Google Scholar 

  5. Suskind AM, Walter LC, Jin C et al (2016) Impact of frailty on complications in patients undergoing common urological procedures: a study from the American college of surgeons national surgical quality improvement database. BJU Int 117(5):836–842. https://doi.org/10.1111/bju.13399

    Article  PubMed  PubMed Central  Google Scholar 

  6. Soma O, Hatakeyama S, Okamoto T et al (2019) Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers. Med Oncol 36(10):88. https://doi.org/10.1007/s12032-019-1313-x

    Article  PubMed  Google Scholar 

  7. Xue QL (2011) The frailty syndrome: definition and natural history. Clin Geriatr Med 27(1):1–15. https://doi.org/10.1016/j.cger.2010.08.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Soma O, Hatakeyama S, Imai A et al (2020) Relationship between frailty and lower urinary tract symptoms among community-dwelling adults. Low Urin Tract Symptoms 12(2):128–136. https://doi.org/10.1111/luts.12292

    Article  PubMed  Google Scholar 

  9. Kodama H, Hatakeyama S, Momota M et al (2020) Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study). Urol Oncol. https://doi.org/10.1016/j.urolonc.2020.06.019

    Article  PubMed  Google Scholar 

  10. Momota M, Hatakeyama S, Soma O et al (2020a) Frailty is a predictor of moderate to severe pain after robot-assisted laparoscopic prostatectomy: a case-control study (FRAP study). BJUI Compass 1(3):100–107. https://doi.org/10.1002/bco2.17

    Article  Google Scholar 

  11. Levy I, Finkelstein M, Bilal KH et al (2017) Modified frailty index associated with Clavien-Dindo IV complications in robot-assisted radical prostatectomies: a retrospective study. Urol Oncol 35(6):425–431. https://doi.org/10.1016/j.urolonc.2017.01.005

    Article  PubMed  Google Scholar 

  12. Taylor BL, Xia L, Guzzo TJ et al (2019) Frailty and greater health care resource utilization following major urologic oncology surgery. Eur Urol Oncol 2(1):21–27. https://doi.org/10.1016/j.euo.2018.06.005

    Article  PubMed  Google Scholar 

  13. Molina-Garrido MJ, Guillen-Ponce C (2017) Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Rev Aging Male 20(2):102–109. https://doi.org/10.1080/13685538.2016.1277516

    Article  Google Scholar 

  14. Droz JP, Albrand G, Gillessen S et al (2017) Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol 72(4):521–531. https://doi.org/10.1016/j.eururo.2016.12.025

    Article  PubMed  Google Scholar 

  15. Momota M, Hatakeyama S, Soma O et al (2020b) Geriatric 8 screening of frailty in patients with prostate cancer. Int J Urol 27(8):642–648. https://doi.org/10.1111/iju.14256

    Article  CAS  PubMed  Google Scholar 

  16. Decoster L, Van Puyvelde K, Mohile S et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 26(2):288–300. https://doi.org/10.1093/annonc/mdu210

    Article  CAS  PubMed  Google Scholar 

  17. Fukushi K, Narita T, Hatakeyama S et al (2017a) Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma. Int J Urol 24(5):361–366. https://doi.org/10.1111/iju.13318

    Article  CAS  PubMed  Google Scholar 

  18. Husson O, de Rooij BH, Kieffer J et al (2020) The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “real-world”: results from the population-based PROFILES registry. Oncologist 25(4):e722–e732. https://doi.org/10.1634/theoncologist.2019-0348

    Article  PubMed  Google Scholar 

  19. Shirk JD, Saigal CS (2017) From QOL to QALYs: Comparing nononcologic outcomes in prostate cancer survivors across treatments. Urol Oncol 35(2):69–75. https://doi.org/10.1016/j.urolonc.2016.07.019

    Article  PubMed  Google Scholar 

  20. Van Hemelrijck M, Sparano F, Moris L et al (2020) Harnessing the patient voice in prostate cancer research: systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making. Cancer Med 9(12):4039–4058. https://doi.org/10.1002/cam4.3018

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chen MN, Ho KY, Hung YN et al (2019) Pre-treatment quality of life as a predictor of distant metastasis-free survival and overall survival in patients with head and neck cancer who underwent free flap reconstruction. Eur J Oncol Nurs 41:1–6. https://doi.org/10.1016/j.ejon.2019.05.003

    Article  PubMed  Google Scholar 

  22. Frantellizzi V, De Feo MS, Di Rocco A et al (2020) Baseline quality of life predicts overall survival in patients with mCRPC treated with (223)Ra-dichloride. Hell J Nucl Med 23(1):12–20. https://doi.org/10.1967/s002449912001

    Article  PubMed  Google Scholar 

  23. Suppanuntaroek S, Hatakeyama S, Fujita N et al (2020) Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma. Int J Clin Oncol 25(2):362–369. https://doi.org/10.1007/s10147-019-01563-2

    Article  CAS  PubMed  Google Scholar 

  24. Quinten C, Kenis C, Hamaker M et al (2020) The added value of geriatric assessment in evaluating a patient’s health-related quality-of-life: a study in ≥70-year-old early-stage invasive breast cancer patients. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.13278

    Article  Google Scholar 

  25. Biesma B, Wymenga ANM, Vincent A et al (2011) Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol 22(7):1520–1527. https://doi.org/10.1093/annonc/mdq637

    Article  CAS  PubMed  Google Scholar 

  26. Knight J, Ayyash K, Colling K et al (2020) A cohort study investigating the relationship between patient reported outcome measures and pre-operative frailty in patients with operable, non-palliative colorectal cancer. BMC Geriatr 20(1):311. https://doi.org/10.1186/s12877-020-01715-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kobayashi K, Takeda F, Teramukai S et al (1998) A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34(6):810–815. https://doi.org/10.1016/s0959-8049(97)00395-x

    Article  CAS  PubMed  Google Scholar 

  28. Fukushi K, Narita T, Hatakeyama S et al (2017b) Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol 22(2):366–372. https://doi.org/10.1007/s10147-016-1071-0

    Article  CAS  PubMed  Google Scholar 

  29. Amiya Y, Yamada Y, Sugiura M et al (2017) Outcomes of patients older than 75 years with non-metastatic prostate cancer. Asian J Urol 4(2):102–106. https://doi.org/10.1016/j.ajur.2016.12.001

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nguyen-Nielsen M, Moller H, Tjonneland A et al (2020) Patient-reported outcome measures after treatment for prostate cancer: results from the Danish prostate cancer registry (DAPROCAdata). Cancer Epidemiol 64:101623. https://doi.org/10.1016/j.canep.2019.101623

    Article  PubMed  Google Scholar 

  31. Cheung AS, de Rooy C, Hoermann R et al (2017) Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clin Endocrinol (Oxf) 86(3):388–394. https://doi.org/10.1111/cen.13249

    Article  CAS  Google Scholar 

  32. Joly F, Oudard S, Fizazi K et al (2020) Quality of life and pain during treatment of metastatic castration-resistant prostate cancer with cabazitaxel in routine clinical practice. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2020.02.003

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Yuki Fujita and Atsuko Sakuraba for their invaluable help with the data collection.

Funding

This study was supported by a grant-in-aid for scientific research (18K09157, 19H05556, 20K09517, 20K18082, 20K18130, 20K18107) from the Japan Society for the Promotion of Science and a research grant from the 31st Japanese Society of Geriatric Urology.

Author information

Authors and Affiliations

  1. Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan

    Tomoko Hamaya, Masaki Momota, Takuma Narita, Hiromichi Iwamura, Yuta Kojima, Itsuto Hamano, Naoki Fujita, Teppei Okamoto, Kyo Togashi, Hayato Yamamoto, Yasuhiro Hashimoto & Chikara Ohyama

  2. Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan

    Shingo Hatakeyama & Chikara Ohyama

  3. Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan

    Tohru Yoneyama, Takahiro Yoneyama & Chikara Ohyama

Authors
  1. Tomoko Hamaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shingo Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Momota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuma Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromichi Iwamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuta Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Itsuto Hamano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naoki Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Teppei Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kyo Togashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tohru Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hayato Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takahiro Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasuhiro Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shingo Hatakeyama.

Ethics declarations

Conflict of interest

All authors have no conflicts of interest to declare.

Ethics statement

All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Consent to participate

Opt-out approach (written consent was not required in exchange for public disclosure of study).

Consent for publication

All authors agreed with the publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

10147_2020_1798_MOESM1_ESM.pdf

Supplementary file1 (PDF 120 kb) Fig. S1. Supplemental figures: The association of G8 and HRQOL. The association of G8 and functioning QOL items (A) and symptom QOL items (B) in the M0 group were evaluated. Magnitude of slopes in the M0 group was evaluated (C). The association of G8 and functioning QOL items (D) and 100 symptom QOL items (E) in the M1 group were evaluated. Magnitude of slopes in the M0 group was evaluated (F). Fig. S2. Supplemental figures: The optimal cutoff value of QOL scores for G8 ≤14. The optimal cutoff value of QOL scores for G8 ≤14 was evaluated using receiver operating characteristic (ROC) curve and the area under the curve (AUC) in the functioning QOL (A), global QOL (B), and 100 symptom QOL (C). Fig. S3. Exploratory outcomes: Comparison of G8 and QOL scores among the treatments and disease stages. The G8 (A) and QOL (B) scores in the M0 group were compared among the RARP, RT, and ADT alone.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamaya, T., Hatakeyama, S., Momota, M. et al. Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study). Int J Clin Oncol 26, 199–206 (2021). https://doi.org/10.1007/s10147-020-01798-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01798-4

Keywords

Search

Navigation